Botanix Pharmaceuticals Limited (AU:BOT) has released an update.
Botanix Pharmaceuticals Limited has successfully secured a $70 million investment through institutional placement to fund the commercial launch of SofdraÔ, a novel FDA-approved treatment for excessive underarm sweating. The capital will support marketing, manufacturing, and corporate expenses, ensuring the company is fully funded for the product’s anticipated launch and first sales in Q4 2024. The investment attracted both new and existing top-tier Australian and international institutional investors, marking a significant milestone for Botanix as they progress into the commercial phase.
For further insights into AU:BOT stock, check out TipRanks’ Stock Analysis page.
